Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.